Blenrep, a cancer drug from GSK (US), significantly reduced the risk of death and is poised to regain regulatory approval.

British pharmaceutical giant GlaxoSmithKline (GSK.US) said its blood cancer drug, when used in combination with another cancer treatment, significantly reduced the risk of death for cancer patients, further improving the prospects of bringing back its cancer drug Blenrep to the market after it was withdrawn by the FDA and European Medicines Agency.